B-intervention	0	11	Progressive
I-intervention	12	20	strength
I-intervention	21	29	training
O	30	32	to
O	33	40	prevent
B-condition	41	52	LYmphoedema
O	53	55	in
O	56	59	the
O	60	65	first
O	66	70	year
O	71	76	after
O	77	83	breast
O	84	90	CAncer
O	91	92	-
O	93	96	the
O	97	101	LYCA
O	102	113	feasibility
O	114	119	study
O	119	120	.

O	121	132	Lymphoedema
O	133	135	is
O	136	137	a
O	138	144	common
O	145	149	late
O	150	156	effect
O	157	162	after
O	163	169	breast
O	170	176	cancer
O	177	178	(
O	178	180	BC
O	180	181	)
O	182	186	that
O	187	190	has
O	191	193	no
O	194	203	effective
O	204	208	cure
O	209	213	once
O	214	221	chronic
O	221	222	.

O	223	235	Accumulating
O	236	244	evidence
O	245	253	supports
O	254	265	progressive
O	266	274	strength
O	275	283	training
O	284	285	(
O	285	288	PRT
O	288	289	)
O	290	292	as
O	293	294	a
O	295	299	safe
O	300	308	exercise
O	309	317	modality
O	318	320	in
O	321	329	relation
O	330	332	to
O	333	336	the
O	337	342	onset
O	343	346	and
O	347	359	exacerbation
O	360	362	of
O	363	374	lymphoedema
O	374	375	.

O	376	378	In
O	379	382	the
O	383	384	'
O	384	394	preventive
O	395	407	intervention
O	408	415	against
O	416	427	LYmphoedema
O	428	433	after
O	434	440	breast
O	441	447	CAncer
O	447	448	'
O	449	450	(
O	450	454	LYCA
O	454	455	)
O	456	467	feasibility
O	468	473	study
O	474	476	we
O	477	485	examined
O	486	489	the
O	490	501	feasibility
O	502	504	of
O	505	506	a
O	507	514	program
O	515	517	of
O	518	521	PRT
O	522	524	in
O	525	528	the
O	529	534	first
O	535	539	year
O	540	545	after
O	546	548	BC
O	549	551	to
O	552	558	inform
O	559	560	a
O	561	568	planned
O	569	579	randomised
O	580	590	controlled
O	591	596	trial
O	597	598	(
O	598	601	RCT
O	601	602	)
O	602	603	.

O	604	608	LYCA
O	609	612	was
O	613	614	a
O	615	618	one
O	618	619	-
O	619	624	group
O	625	636	prospective
O	637	642	pilot
O	643	648	trial
O	649	657	inviting
O	658	663	women
O	664	672	operated
O	673	677	with
O	678	686	axillary
O	687	692	lymph
O	693	697	node
O	698	708	dissection
O	709	712	for
O	713	723	unilateral
O	724	731	primary
O	732	734	BC
O	734	735	.

O	736	748	Participants
O	749	758	exercised
O	759	764	three
O	765	770	times
O	771	772	a
O	773	777	week
O	778	781	for
O	782	784	50
O	785	790	weeks
O	791	792	(
O	792	794	20
O	795	800	weeks
O	801	811	supervised
O	812	820	followed
O	821	823	by
O	824	826	30
O	827	832	weeks
O	833	837	home
O	837	838	-
O	838	843	based
O	844	852	exercise
O	852	853	)
O	853	854	.

O	855	858	The
O	859	866	program
O	867	874	ensured
O	875	879	slow
O	880	894	individualised
O	895	906	progression
O	907	913	during
O	914	917	the
O	918	926	exercise
O	927	934	program
O	934	935	.

O	936	939	The
O	940	947	primary
O	948	955	outcome
O	956	959	was
B-outcome-Measure	960	971	feasibility
O	972	980	measured
O	981	983	by
O	984	995	eligibility
O	996	999	and
O	1000	1011	recruitment
O	1012	1017	rates
O	1017	1018	,
O	1019	1021	as
O	1022	1026	well
O	1027	1029	as
O	1030	1043	questionnaire
O	1043	1044	-
O	1044	1052	assessed
B-outcome-Measure	1053	1065	satisfaction
O	1066	1069	and
B-outcome-Measure	1070	1079	adherence
I-outcome-Measure	1080	1082	to
I-outcome-Measure	1083	1091	exercise
O	1091	1092	.

O	1093	1104	Furthermore
O	1104	1105	,
O	1106	1108	we
O	1109	1117	assessed
B-outcome-Measure	1118	1121	arm
I-outcome-Measure	1122	1131	interlimb
I-outcome-Measure	1132	1138	volume
I-outcome-Measure	1139	1149	difference
O	1150	1152	by
O	1153	1158	water
O	1159	1171	displacement
O	1171	1172	,
B-outcome-Measure	1173	1179	muscle
I-outcome-Measure	1180	1188	strength
O	1189	1191	by
O	1192	1199	dynamic
O	1200	1203	and
O	1204	1213	isometric
O	1214	1220	muscle
O	1221	1228	testing
O	1229	1232	and
B-outcome-Measure	1233	1238	range
I-outcome-Measure	1239	1241	of
I-outcome-Measure	1242	1250	movement
I-outcome-Measure	1251	1253	in
I-outcome-Measure	1254	1257	the
I-outcome-Measure	1258	1266	shoulder
O	1267	1269	by
O	1270	1280	goniometry
O	1280	1281	.

O	1282	1284	In
O	1285	1291	August
O	1292	1296	2015
O	1296	1297	,
B-total-participants	1298	1303	eight
O	1304	1306	of
B-total-participants	1307	1309	11
O	1310	1318	eligible
O	1319	1327	patients
O	1328	1336	accepted
O	1337	1350	participation
O	1350	1351	.

O	1352	1355	Two
O	1356	1358	of
O	1359	1363	them
B-outcome	1364	1371	dropped
I-outcome	1372	1375	out
O	1376	1381	early
O	1382	1385	due
O	1386	1388	to
O	1389	1394	other
O	1395	1401	health
O	1402	1408	issues
O	1408	1409	.

O	1410	1413	The
O	1414	1423	remaining
O	1424	1427	six
O	1428	1440	participants
O	1441	1444	had
B-outcome	1445	1449	high
I-outcome	1450	1458	exercise
I-outcome	1459	1468	adherence
O	1469	1476	through
O	1477	1480	the
O	1481	1491	supervised
O	1492	1498	period
O	1498	1499	,
O	1500	1503	but
O	1504	1508	only
O	1509	1514	three
O	1515	1525	maintained
O	1526	1530	this
O	1531	1538	through
O	1539	1542	the
O	1543	1547	home
O	1548	1556	exercise
O	1557	1563	period
O	1563	1564	.

O	1565	1572	Program
B-outcome	1573	1585	satisfaction
O	1586	1589	was
O	1590	1594	high
O	1595	1598	and
O	1599	1601	no
B-outcome	1602	1609	serious
I-outcome	1610	1617	adverse
I-outcome	1618	1624	events
O	1625	1629	from
O	1630	1637	testing
O	1638	1640	or
O	1641	1651	exercising
O	1652	1656	were
O	1657	1665	reported
O	1665	1666	.

O	1667	1670	One
O	1671	1682	participant
O	1683	1692	presented
O	1693	1697	with
B-outcome	1698	1709	lymphoedema
O	1710	1712	at
O	1713	1715	50
O	1715	1716	-
O	1716	1720	week
O	1721	1727	follow
O	1727	1728	-
O	1728	1730	up
O	1730	1731	.

B-outcome	1732	1738	Muscle
I-outcome	1739	1747	strength
O	1748	1756	markedly
O	1757	1766	increased
O	1767	1771	with
O	1772	1782	supervised
O	1783	1791	exercise
O	1791	1792	,
O	1793	1796	but
O	1797	1800	was
O	1801	1804	not
O	1805	1810	fully
O	1811	1821	maintained
O	1822	1829	through
O	1830	1833	the
O	1834	1838	home
O	1839	1847	exercise
O	1848	1854	period
O	1854	1855	.

B-outcome	1856	1861	Range
I-outcome	1862	1864	of
I-outcome	1865	1873	shoulder
I-outcome	1874	1882	movement
O	1883	1886	was
O	1887	1890	not
O	1891	1901	negatively
O	1902	1910	affected
O	1911	1913	by
O	1914	1917	the
O	1918	1925	program
O	1925	1926	.

O	1927	1938	Recruitment
O	1938	1939	,
O	1940	1947	testing
O	1947	1948	,
O	1949	1952	and
O	1953	1961	exercise
O	1962	1964	in
O	1965	1969	LYCA
O	1970	1973	was
O	1974	1978	safe
O	1979	1982	and
O	1983	1991	feasible
O	1991	1992	.

O	1993	1995	At
O	1996	1999	the
O	2000	2002	50
O	2002	2003	-
O	2003	2007	week
O	2008	2014	follow
O	2014	2015	-
O	2015	2017	up
O	2017	2018	,
O	2019	2024	there
O	2025	2028	was
O	2029	2032	one
O	2033	2037	case
O	2038	2040	of
O	2041	2052	lymphoedema
O	2052	2053	.

O	2054	2057	The
O	2058	2062	LYCA
O	2063	2070	program
O	2071	2075	will
O	2076	2078	be
O	2079	2086	further
O	2087	2093	tested
O	2094	2096	in
O	2097	2098	a
O	2099	2103	full
O	2103	2104	-
O	2104	2109	scale
O	2110	2113	RCT
O	2113	2114	.
